Clinical Trial Update: Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing intravenous CXA 101/tazobactam with metronidazole and meropenem in complicated intraabdominal infections has completed with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Intra-abdominal Infection

Drugs mentioned

• CXA-101/Tazobactam (CXA-101/tazobactam)
• METRONIDAZOLE (Metronidazole)
• Meropenem (Meropenem)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Complicated Intra-abdominal Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-01-16